AR119683A1 - Anticuerpos y receptores de antígeno quimérico específicos para receptor huérfano 1 similar a receptor de tirosina quinasa (ror1) - Google Patents
Anticuerpos y receptores de antígeno quimérico específicos para receptor huérfano 1 similar a receptor de tirosina quinasa (ror1)Info
- Publication number
- AR119683A1 AR119683A1 ARP200100209A ARP200100209A AR119683A1 AR 119683 A1 AR119683 A1 AR 119683A1 AR P200100209 A ARP200100209 A AR P200100209A AR P200100209 A ARP200100209 A AR P200100209A AR 119683 A1 AR119683 A1 AR 119683A1
- Authority
- AR
- Argentina
- Prior art keywords
- ror1
- antibodies
- tyrosine kinase
- receptors
- chimeric antigen
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title 1
- 102000016978 Orphan receptors Human genes 0.000 title 1
- 108070000031 Orphan receptors Proteins 0.000 title 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title 1
- 108020003175 receptors Proteins 0.000 abstract 3
- 102000005962 receptors Human genes 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 102000005435 Receptor Tyrosine Kinase-like Orphan Receptors Human genes 0.000 abstract 1
- 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 abstract 1
- 238000011467 adoptive cell therapy Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2857—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, orphan receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
Se proveen moléculas de unión a receptores huérfanos 1 similares a receptor de tirosina quinasa (ROR1), en particular, a anticuerpos humanos específicos para ROR1, incluyendo fragmentos de anticuerpos. La presente divulgación también se relaciona con receptores recombinantes, incluyendo receptores de antígenos quiméricos (CARs) que contienen a dichos anticuerpos o fragmentos, y polinucleótidos que codifican los anticuerpos, fragmentos de unión a antígeno o receptores específicos para ROR1. La divulgación se relaciona adicionalmente a células modificadas genéticamente, que contienen a dichas proteínas de unión a ROR1 y receptores, y métodos relacionados y usos de los mismos en terapia celular adoptiva.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962798456P | 2019-01-29 | 2019-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR119683A1 true AR119683A1 (es) | 2022-01-05 |
Family
ID=69724158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200100209A AR119683A1 (es) | 2019-01-29 | 2020-01-28 | Anticuerpos y receptores de antígeno quimérico específicos para receptor huérfano 1 similar a receptor de tirosina quinasa (ror1) |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220096651A1 (es) |
EP (1) | EP3917570A1 (es) |
JP (1) | JP2022518925A (es) |
KR (1) | KR20210122272A (es) |
CN (1) | CN113365660A (es) |
AR (1) | AR119683A1 (es) |
AU (1) | AU2020215576A1 (es) |
BR (1) | BR112021014833A2 (es) |
CA (1) | CA3123303A1 (es) |
CL (1) | CL2021001986A1 (es) |
CO (1) | CO2021011327A2 (es) |
EA (1) | EA202192103A1 (es) |
IL (1) | IL285182A (es) |
MA (1) | MA54863A (es) |
MX (1) | MX2021009087A (es) |
PE (1) | PE20212198A1 (es) |
SG (1) | SG11202107976SA (es) |
TW (1) | TW202043280A (es) |
WO (1) | WO2020160050A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2818103T3 (es) | 2015-01-16 | 2021-04-09 | Juno Therapeutics Inc | Anticuerpos y receptores de antígenos quiméricos específicos para ROR1 |
US11066475B2 (en) * | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
WO2022029660A1 (en) * | 2020-08-05 | 2022-02-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods |
AU2021334677A1 (en) * | 2020-08-24 | 2023-03-02 | Epimab Biotherapeutics (Hk) Limited | Anti-ROR1 antibodies and related bispecific binding proteins |
WO2022098787A1 (en) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
CN116601170A (zh) * | 2020-12-10 | 2023-08-15 | 上海药明生物技术有限公司 | 抗p-钙粘蛋白抗体及其用途 |
WO2022187406A1 (en) | 2021-03-03 | 2022-09-09 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
US20240018237A1 (en) * | 2021-03-09 | 2024-01-18 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Ror1 binding protein and use thereof |
JP2024517863A (ja) | 2021-05-06 | 2024-04-23 | ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞を刺激し、形質導入する方法 |
WO2023154890A2 (en) * | 2022-02-11 | 2023-08-17 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding steap1 |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023225569A1 (en) | 2022-05-17 | 2023-11-23 | Umoja Biopharma, Inc. | Manufacturing viral particles |
US11932703B2 (en) | 2022-05-24 | 2024-03-19 | Caribou Biosciences, Inc. | Anti-ROR1 antibody and ROR1-targeting engineered cells |
WO2023240282A1 (en) | 2022-06-10 | 2023-12-14 | Umoja Biopharma, Inc. | Engineered stem cells and uses thereof |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
CN115724973B (zh) * | 2022-09-26 | 2023-07-11 | 普健生物(武汉)科技有限公司 | 抗人ror1高亲和力兔单克隆抗体及其应用 |
WO2024073583A1 (en) * | 2022-09-30 | 2024-04-04 | Caribou Biosciences, Inc. | Anti-ror1 chimeric antigen receptors (cars), car-nk cells and related methods |
Family Cites Families (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
EP0090505B1 (en) | 1982-03-03 | 1990-08-08 | Genentech, Inc. | Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it |
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
IN165717B (es) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5565566A (en) | 1987-04-24 | 1996-10-15 | Discovery Therapeutics, Inc. | N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5298508A (en) | 1988-07-19 | 1994-03-29 | The United States Of America As Represented By The Department Of Health And Human Services | Irreversible inhibitors of adenosine receptors |
DE68919715T2 (de) | 1988-12-28 | 1995-04-06 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
US5424297A (en) | 1992-04-27 | 1995-06-13 | University Of Virginia Alumni Patents Foundation | Adenosine dextran conjugates |
DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
PL174494B1 (pl) | 1992-11-13 | 1998-08-31 | Idec Pharma Corp | Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
AU6781194A (en) | 1993-05-03 | 1994-11-21 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists |
US5504090A (en) | 1994-03-30 | 1996-04-02 | Trustees Of The University Of Pennsylvania | Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US5670501A (en) | 1994-09-01 | 1997-09-23 | Discovery Therapeutics, Inc. | N-substituted 9-alkyladenines |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
ATE548351T1 (de) | 1996-01-29 | 2012-03-15 | Us Of America Represented By The Secretary Dept Of Health And Human Services | Dihydropyridin-pyridin-, benzopyranon- und triazolochinazolin-derivate, deren herstellung und verwendung als adenosinrezeptor-antagonisten |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
DE69717831T3 (de) | 1996-07-24 | 2018-08-30 | Celgene Corp. | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
EP0920505B1 (en) | 1996-08-16 | 2008-06-04 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US5786360A (en) | 1996-11-19 | 1998-07-28 | Link Technology Incorporated | A1 adenosine receptor antagonists |
ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
CA2308114A1 (en) | 1997-10-21 | 1999-04-29 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
CA2319236A1 (en) | 1998-02-09 | 1999-08-12 | Genentech, Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
TR200002681T2 (tr) | 1998-03-16 | 2000-12-21 | Celgene Corporation | 2-(2,6-Dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı |
EP1073465B1 (en) | 1998-04-15 | 2005-06-22 | The Brigham And Women's Hospital, Inc. | T cell inhibitory receptor compositions and uses thereof |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
US6326390B1 (en) | 1998-08-25 | 2001-12-04 | King Pharmaceuticals Reseach And Development, Inc. | Use of adenosine A3 receptor antagonists to inhibit tumor growth |
EP1109921A4 (en) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | FOR PROSTATE-SPECIFIC MEMBRANE-ANTI-SPECIFIC FUSION RECEPTORS AND THEIR USE |
US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US6313131B1 (en) | 1999-02-16 | 2001-11-06 | Upsher-Smith Laboratories, Inc. | Method of kidney treatment |
TR200102688T2 (tr) | 1999-03-18 | 2002-01-21 | Celgene Corporation | İkameli 1-okso ve 1,3-dioksoizoindolinler ve enflamatuar sitokin seviyelerinin azaltılması için farmasötik bileşimlerde kullanımları. |
EP3031917A1 (en) | 1999-04-09 | 2016-06-15 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
PT1196186E (pt) | 1999-07-12 | 2008-02-14 | Genentech Inc | Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral. |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
PT1242438E (pt) | 1999-12-29 | 2007-02-28 | Immunogen Inc | Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico |
EP1287357A2 (en) | 2000-06-02 | 2003-03-05 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
WO2002031140A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
DE60122765D1 (de) | 2000-11-07 | 2006-10-12 | Hope City | Cd19-spezifische umgezielte immunzellen |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
WO2002068414A2 (en) | 2001-02-27 | 2002-09-06 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
DK1465634T3 (da) | 2001-12-12 | 2015-01-26 | Us Government | Fremgangsmåde til anvendelse af adenosinreceptorinhibitorer til at forstærke immunrespons og inflammation |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
WO2003085102A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose |
US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US20040047858A1 (en) | 2002-09-11 | 2004-03-11 | Blumberg Richard S. | Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof |
ES2633311T3 (es) | 2002-12-16 | 2017-09-20 | Genentech, Inc. | Variantes de inmunoglobulina y usos de las mismas |
ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
AU2004244626A1 (en) | 2003-05-23 | 2004-12-09 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
CN1871359B (zh) | 2003-10-22 | 2010-11-17 | 凯克研究生院 | 使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法 |
ME03330B (me) | 2003-11-05 | 2019-10-20 | Roche Glycart Ag | Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
JP2007518399A (ja) | 2003-12-02 | 2007-07-12 | ジェンザイム コーポレイション | 肺癌を診断および治療する組成物並びに方法 |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
WO2006083289A2 (en) | 2004-06-04 | 2006-08-10 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
US7521541B2 (en) | 2004-09-23 | 2009-04-21 | Genetech Inc. | Cysteine engineered antibodies and conjugates |
ES2432091T5 (es) | 2005-03-25 | 2022-03-18 | Gitr Inc | Moléculas de unión GITR y usos de las mismas |
EP2161336B2 (en) | 2005-05-09 | 2017-03-29 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
PL1899364T3 (pl) | 2005-05-17 | 2020-08-24 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
CN102796743B (zh) | 2006-01-13 | 2015-11-18 | 美国政府健康及人类服务部国立卫生研究院 | 用于在哺乳动物细胞中表达的密码子优化的IL-15和IL-15Rα基因 |
US20110212086A1 (en) | 2006-01-19 | 2011-09-01 | Genzyme Corporation | GITR Antibodies For The Treatment of Cancer |
US20100178299A1 (en) | 2007-02-13 | 2010-07-15 | Northeastern University | Methods and compositions for improving immune responses |
HUE038506T2 (hu) | 2007-03-30 | 2018-10-29 | Memorial Sloan Kettering Cancer Center | Kostimuláló ligand konstitutív expressziója adoptív módon átvitt T-limfocitákon |
US7615883B2 (en) | 2007-06-06 | 2009-11-10 | Meheen H Joe | Wind driven venturi turbine |
CN102131828B (zh) | 2007-06-18 | 2015-06-17 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
NZ616254A (en) | 2007-06-27 | 2015-04-24 | Us Sec Dep Of Health And Human Services | Complexes of il-15 and il-15ralpha and uses thereof |
WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
JP2011500730A (ja) | 2007-10-26 | 2011-01-06 | ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント | Tim−3を用いた治療および診断方法 |
ES2374863T3 (es) | 2007-12-07 | 2012-02-22 | Miltenyi Biotec Gmbh | Centrífuga para separar una muestra en por lo menos dos componentes. |
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
ES2639857T3 (es) | 2008-02-11 | 2017-10-30 | Cure Tech Ltd. | Anticuerpos monoclonales para el tratamiento del tumor |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
GB0906579D0 (en) | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
NZ590667A (en) | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
CN102149820B (zh) | 2008-09-12 | 2014-07-23 | 国立大学法人三重大学 | 能够表达外源gitr配体的细胞 |
WO2010065959A1 (en) | 2008-12-05 | 2010-06-10 | Northeastern University | Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
CA2759733C (en) | 2009-04-23 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
KR101875227B1 (ko) | 2009-04-30 | 2018-07-05 | 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드. | 항-ceacam1 항체들과 이를 이용하는 방법들 |
NZ714757A (en) | 2009-08-14 | 2018-07-27 | Us Gov Health & Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
CN103951753B (zh) | 2009-09-03 | 2018-01-12 | 默沙东公司 | 抗‑gitr抗体 |
GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
ES2717629T3 (es) | 2009-11-03 | 2019-06-24 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
LT2519543T (lt) | 2009-12-29 | 2016-10-10 | Emergent Product Development Seattle, Llc | Heterodimerus rišantys baltymai ir jų panaudojimas |
US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
WO2012048340A2 (en) | 2010-10-08 | 2012-04-12 | President And Fellows Of Harvard College | High-throughput immune sequencing |
ES2966040T3 (es) | 2010-10-08 | 2024-04-18 | Harvard College | Alto rendimiento de células individuales con código de barra |
CA2818992C (en) | 2010-12-01 | 2021-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ror1 antibodies |
DK2649086T3 (en) | 2010-12-09 | 2017-09-18 | Univ Pennsylvania | USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER |
RU2688185C2 (ru) | 2011-03-23 | 2019-05-21 | Фред Хатчинсон Кэнсер Рисерч Сентер | Способ и композиции для клеточной иммунотерапии |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
EP2776451B1 (en) | 2011-11-11 | 2018-07-18 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
WO2013082366A1 (en) | 2011-12-01 | 2013-06-06 | The Brigham And Women's Hospital, Inc. | Anti-ceacam1 recombinant antibodies for cancer therapy |
EP2804625A4 (en) | 2012-01-17 | 2015-10-28 | Univ Northeastern | METHODS AND COMPOSITIONS FOR IN VITRO DEVELOPMENT OF IMMUNOSUPPRESSANT REGULATORS AND USES THEREOF |
EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
NZ702108A (en) | 2012-05-03 | 2016-09-30 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
EP3698809A1 (en) | 2012-07-31 | 2020-08-26 | The Brigham & Women's Hospital, Inc. | Modulation of the immune response using agents binding tim-3 and ceacam-1 |
WO2014031687A1 (en) | 2012-08-20 | 2014-02-27 | Jensen, Michael | Method and compositions for cellular immunotherapy |
MX362456B (es) | 2012-08-24 | 2019-01-18 | Univ California | Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis. |
CN104853766A (zh) | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
CA2887528C (en) | 2012-10-12 | 2023-08-29 | The Brigham And Women's Hospital, Inc. | Enhancement of the immune response |
WO2014097442A1 (ja) | 2012-12-20 | 2014-06-26 | 三菱電機株式会社 | 車載装置及びプログラム |
US9701758B2 (en) | 2013-05-24 | 2017-07-11 | Board Of Regents, The University Of Texas System | Anti-CD19 scFv (FMC63) polypeptide |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
MX2016007927A (es) | 2013-12-20 | 2016-09-13 | Hutchinson Fred Cancer Res | Moleculas efectoras quimericas etiquetadas y receptores de las mismas. |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
ES2770684T3 (es) | 2014-03-14 | 2020-07-02 | Novartis Ag | Moléculas de anticuerpos contra LAG-3 y usos de los mismos |
CA2950381C (en) * | 2014-07-29 | 2021-02-23 | Cellectis | Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy |
JP6672310B2 (ja) | 2014-09-15 | 2020-03-25 | アブビトロ, エルエルシー | ハイスループットヌクレオチドライブラリーシークエンシング |
ES2818103T3 (es) * | 2015-01-16 | 2021-04-09 | Juno Therapeutics Inc | Anticuerpos y receptores de antígenos quiméricos específicos para ROR1 |
US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
CA2983937A1 (en) | 2015-04-27 | 2016-11-03 | Abvitro Llc | Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens |
AU2016345681A1 (en) * | 2015-10-30 | 2018-05-10 | Nbe-Therapeutics Ag | Anti-ROR1 antibodies |
CN110573177A (zh) * | 2017-04-28 | 2019-12-13 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有人源化靶向结构域的ror1特异性嵌合抗原受体(car) |
CN107557337B (zh) * | 2017-09-15 | 2020-06-26 | 山东兴瑞生物科技有限公司 | 一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用 |
US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
-
2020
- 2020-01-28 CN CN202080011694.2A patent/CN113365660A/zh active Pending
- 2020-01-28 PE PE2021001239A patent/PE20212198A1/es unknown
- 2020-01-28 AU AU2020215576A patent/AU2020215576A1/en active Pending
- 2020-01-28 MX MX2021009087A patent/MX2021009087A/es unknown
- 2020-01-28 MA MA054863A patent/MA54863A/fr unknown
- 2020-01-28 JP JP2021544129A patent/JP2022518925A/ja active Pending
- 2020-01-28 EP EP20707989.8A patent/EP3917570A1/en active Pending
- 2020-01-28 SG SG11202107976SA patent/SG11202107976SA/en unknown
- 2020-01-28 EA EA202192103A patent/EA202192103A1/ru unknown
- 2020-01-28 CA CA3123303A patent/CA3123303A1/en active Pending
- 2020-01-28 AR ARP200100209A patent/AR119683A1/es unknown
- 2020-01-28 US US17/421,365 patent/US20220096651A1/en active Pending
- 2020-01-28 WO PCT/US2020/015489 patent/WO2020160050A1/en active Application Filing
- 2020-01-28 BR BR112021014833-7A patent/BR112021014833A2/pt unknown
- 2020-01-28 KR KR1020217027154A patent/KR20210122272A/ko active Search and Examination
- 2020-01-30 TW TW109102879A patent/TW202043280A/zh unknown
-
2021
- 2021-07-28 IL IL285182A patent/IL285182A/en unknown
- 2021-07-29 CL CL2021001986A patent/CL2021001986A1/es unknown
- 2021-08-27 CO CONC2021/0011327A patent/CO2021011327A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021009087A (es) | 2021-09-08 |
PE20212198A1 (es) | 2021-11-16 |
CL2021001986A1 (es) | 2022-04-01 |
US20220096651A1 (en) | 2022-03-31 |
SG11202107976SA (en) | 2021-08-30 |
JP2022518925A (ja) | 2022-03-17 |
KR20210122272A (ko) | 2021-10-08 |
EP3917570A1 (en) | 2021-12-08 |
WO2020160050A1 (en) | 2020-08-06 |
CO2021011327A2 (es) | 2021-09-09 |
BR112021014833A2 (pt) | 2021-10-05 |
EA202192103A1 (ru) | 2021-12-15 |
MA54863A (fr) | 2021-12-08 |
CA3123303A1 (en) | 2020-08-06 |
CN113365660A (zh) | 2021-09-07 |
AU2020215576A1 (en) | 2021-07-08 |
IL285182A (en) | 2021-09-30 |
TW202043280A (zh) | 2020-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR119683A1 (es) | Anticuerpos y receptores de antígeno quimérico específicos para receptor huérfano 1 similar a receptor de tirosina quinasa (ror1) | |
PE20211058A1 (es) | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d) | |
CL2016001134A1 (es) | Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento. | |
AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
MD3652215T2 (ro) | Moleculă polipeptidică îmbunătăţită cu specificitate duală | |
MX2020010235A (es) | Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos. | |
CR20190276A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
BRPI0507433B8 (pt) | anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit | |
AR079274A1 (es) | Proteinas de enlace a antigenos (humanas) que enlazan (beta)-klotho, receptores fgf y complejo de los mismos | |
AR052285A1 (es) | Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas | |
ECSP12011698A (es) | Anticuerpos cea | |
EA202192024A1 (ru) | Рецепторы, обеспечивающие прицельную костимуляцию, для адоптивной клеточной терапии | |
CU20170023A7 (es) | Anticuerpos y receptores de antígeno quiméricos específicos para cd19 | |
AR067199A1 (es) | Proteinas de union a antigenos que se unen a par-2 | |
CO6270358A2 (es) | Anticuerpos para gdf8 asi como sus usos | |
AU2019243448B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
AR063090A1 (es) | Proteinas de union al antigeno del receptor de la il-17 | |
CL2008002015A1 (es) | Anticuerpo anti-receptor del factor de creciemiento de hepatocito (hgf)/receptor c-met; hibridoma que lo produce; acido nucleico que lo codifica; vector y celula huesped que los comprende; procedimiento de produccion; composicion que los comprende; su uso para tratar cancer; y metodo de diagnostico in vitro | |
BR112018012826A2 (pt) | método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1 | |
BR112022013756A2 (pt) | Anticorpos anti-trem2 e métodos de uso dos mesmos | |
SG10201803473WA (en) | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide | |
AR116048A1 (es) | Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión | |
WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
BR112021016272A2 (pt) | Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos | |
BR112017022205A2 (pt) | anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada |